The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Kisplyx lenvatinib Accelerated assessment | Eisai GmbH | Carcinoma, Renal Cell | 🇪🇺 EU 2016-08-25 | Order → |
| Atazanavir Viatris (previously Atazanavir Mylan) atazanavir Generic | Viatris Limited | HIV Infections | 🇪🇺 EU 2016-08-22 | Order → |
| Aerivio Spiromax salmeterol;fluticasone propionate | Teva B.V. | Pulmonary Disease, Chronic Obstructive; Asthma | 🇪🇺 EU 2016-08-18 | Order → |
| Airexar Spiromax salmeterol xinafoate;fluticasone propionate | Teva B.V. | Pulmonary Disease, Chronic Obstructive; Asthma | 🇪🇺 EU 2016-08-18 | Order → |
| Nordimet methotrexate | Nordic Group B.V. | Arthritis, Psoriatic; Psoriasis; Arthritis, Juvenile Rheumatoid; Arthritis, Rheumatoid | 🇪🇺 EU 2016-08-18 | Order → |
| Zalmoxis allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (ΔLNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2) ATMPConditional | MolMed SpA | Hematopoietic Stem Cell Transplantation; Graft vs Host Disease | 🇪🇺 EU 2016-08-18 | Order → |
| Cinqaero reslizumab | Teva B.V. | Asthma | 🇪🇺 EU 2016-08-15 | Order → |
| Bortezomib Hospira bortezomib Generic | Pfizer Europe MA EEIG | Multiple Myeloma | 🇪🇺 EU 2016-07-22 | Order → |
| Bortezomib Sun bortezomib Generic | SUN Pharmaceutical Industries (Europe) B.V. | Multiple Myeloma | 🇪🇺 EU 2016-07-22 | Order → |
| Pemetrexed Fresenius Kabi pemetrexed Generic | Fresenius Kabi Deutschland GmbH | Carcinoma, Non-Small-Cell Lung; Mesothelioma | 🇪🇺 EU 2016-07-22 | Order → |
| Zepatier elbasvir;grazoprevir | Merck Sharp & Dohme B.V. | Hepatitis C, Chronic | 🇪🇺 EU 2016-07-22 | Order → |
| Qtern saxagliptin;dapagliflozin | Astra Zeneca AB | Diabetes Mellitus, Type 2; Diabetes Mellitus; Nutritional and Metabolic Diseases; Metabolic Diseases; Glucose Metabolism Disorders | 🇪🇺 EU 2016-07-15 | Order → |
| EndolucinBeta lutetium (177Lu) chloride | ITM Medical Isotopes GmbH | Radionuclide Imaging | 🇪🇺 EU 2016-07-06 | Order → |
| Epclusa sofosbuvir;velpatasvir Accelerated assessment | Gilead Sciences Ireland UC | Hepatitis C, Chronic | 🇪🇺 EU 2016-07-06 | Order → |
| Zinbryta daclizumab Additional monitoring | Biogen Idec Ltd | Multiple Sclerosis | 🇪🇺 EU 2016-07-01 | Order → |
| Enzepi pancreas powder Additional monitoring | Allergan Pharmaceuticals International Limited | Exocrine Pancreatic Insufficiency | 🇪🇺 EU 2016-06-29 | Order → |
| Ongentys opicapone | Bial - Portela Cª, S.A. | Parkinson Disease | 🇪🇺 EU 2016-06-24 | Order → |
| Zavicefta ceftazidime;avibactam | Pfizer Ireland Pharmaceuticals Unlimited Company | Pneumonia, Bacterial; Soft Tissue Infections; Pneumonia; Urinary Tract Infections; Gram-Negative Bacterial Infections | 🇪🇺 EU 2016-06-23 | Order → |
| Odefsey emtricitabine;rilpivirine;tenofovir alafenamide | Gilead Sciences Ireland UC | HIV Infections | 🇪🇺 EU 2016-06-21 | Order → |
| Flixabi infliximab Biosimilar | Samsung Bioepis NL B.V. | Arthritis, Psoriatic; Spondylitis, Ankylosing; Colitis, Ulcerative; Arthritis, Rheumatoid; Crohn Disease; Psoriasis | 🇪🇺 EU 2016-05-26 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.